{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-027998","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.510489+00:00","generated_at":"2026-06-04T05:36:18.797642+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing","bullets":["Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.","Gross license royalties $4.5M under Mayne License; net recognized $1.3M revenue and $0.5M other income.","Operating expenses fell 85.4% to $9.8M, reflecting transition from commercial pharma to royalty model.","Cash and equivalents $4.3M at Dec 31, 2023; company continues exploring strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-027998","json":"https://secwatch.observer/filing/0001213900-24-027998.json","markdown":"https://secwatch.observer/filing/0001213900-24-027998.md","text":"https://secwatch.observer/filing/0001213900-24-027998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/0001213900-24-027998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/ea0202833-8k_therape.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:36:18.797642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"908bfd5dc6d001137bbb3807c6e682eaae9565ca","claim":"TherapeuticsMD, Inc. reported the full year ended December 31, 2023 results: net income Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, EPS $(0.74) per basic and diluted common share.","evidence_excerpt":"TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/0001213900-24-027998-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share"},{"label":"EPS","value":"$(0.74) per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}